Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Revenue: 2017-2024

Historic Revenue for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $221.9 million.

  • BridgeBio Pharma's Revenue rose 4318.01% to $120.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.8 million, marking a year-over-year increase of 62.46%. This contributed to the annual value of $221.9 million for FY2024, which is 2285.27% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Revenue of $221.9 million as of FY2024, which was up 2,285.27% from $9.3 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Revenue registered a high of $221.9 million during FY2024, and its lowest value of $8.2 million during FY2020.
  • Its 3-year average for Revenue is $103.0 million, with a median of $77.6 million in 2022.
  • In the last 5 years, BridgeBio Pharma's Revenue plummeted by 88.02% in 2023 and then soared by 2,285.27% in 2024.
  • BridgeBio Pharma's Revenue (Yearly) stood at $8.2 million in 2020, then soared by 578.87% to $56.0 million in 2021, then surged by 38.66% to $77.6 million in 2022, then slumped by 88.02% to $9.3 million in 2023, then skyrocketed by 2,285.27% to $221.9 million in 2024.